Ro-15-4513
Sign in to saveAlso known as Ro-154513
Ro15-4513 is a weak partial inverse agonist of the benzodiazepine class of drugs, developed by Hoffmann–La Roche in the 1980s. It acts as an inverse agonist (which acts in a similar way as a competitive antagonist). The drug has been explored as possible antidote to the sedative and cognitively impairing effects of ethanol.
Research
467 papers- RO 15-4513 and its interaction with ethanol.Advances in alcohol & substance abuse · 1988
- Ro 15-4513 Antagonizes Alcohol-Induced Sedation in Mice Through αβγ2-type GABA(A) Receptors.Frontiers in neuroscience · 2011
- The effects of Ro 15-4513 on the behavioral actions of ethanol in an operant reaction time task and a conflict test.Pharmacology, biochemistry, and behavior · 1988
- Cerebellar GABAA receptors and alcohol-related behaviors: focus on diazepam-insensitive [3H]Ro 15-4513 binding.Advances in biochemical psychopharmacology · 1992
- Ro 15-4513 binding to GABAA receptors: subunit composition determines ligand efficacy.Pharmacology, biochemistry, and behavior · 1992
via PubMed
~5 min read
Encyclopedic overview
6 sectionsContents
- Uses
- Photoaffinity label
- Alcohol antidote
- Current use in PET Imaging
- See also
- References
Ro15-4513 is a weak partial inverse agonist of the benzodiazepine class of drugs, developed by Hoffmann–La Roche in the 1980s. It acts as an inverse agonist (which acts in a similar way as a competitive antagonist). The drug has been explored as possible antidote to the sedative and cognitively impairing effects of ethanol.
Ro15-4513 is structurally related to the benzodiazepine antidote flumazenil.
Excerpted from Wikipedia’s “Ro-15-4513” article, available under the CC BY-SA 4.0 licence.